Earnings Call · Q2 FY2022·2022-08-04

Q2 22EPS +8.57%·Rev n/aQ1 22EPS 0.00%·Rev n/aQ4 21EPS +66.67%·Rev n/aQ3 21EPS -13.79%·Rev n/a⚠ consensus missing

BIOCRYST PHARMACEUTICALS INC BCRX

John Bluth — Investor Relations or Corporate Communications

Jon Stonehouse — Chief Executive Officer

Charles Gayer — Chief Commercial Officer

Anthony Doyle — Chief Financial Officer

Helen Thackray — Chief Development Officer

+23.2%1d on move date+23.3% vs SPY3d+27.4%5d+32.4%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more BCRX calls or request research access.

More BCRX calls Browse calls Request research access